JHLT: The Podcast

Today, JHLT: The Podcast discusses the recent ISHLT consensus document "Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—An ISHLT Consensus Document."

Now available online at JHLT—and a helpful companion perspective piece from the authors appears in the print October issue of JHLT.

Today's guests are co-leads on the document, Jens Gottlieb, MD, of Hannover Medical School and Kieran Halloran, MD, MSc, of the University of Alberta.

They discuss:

• Why rapid increases in usage of "BLAD" in the literature meant it was time for a formal definition
• Major considerations and areas of debate during the writing process
• How clinicians should think about patients meeting the criteria for BLAD and how the evaluation of underlying etiologies took place
• Interpreting BLAD's potential relationship to CLAD

Stay up to date with official standards and guidelines documents from ISHLT at ISHLT.org. For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, JHLT: The Podcast continues the Pulmonary Hypertension theme for the month, exploring the study "Long-Term outcomes of stent-based pulmonary angioplasty for isolated peripheral pulmonary artery stenosis," which appears in the September print issue of JHLT.

Today's guest is author Hiroto Shimokawahara, MD, of the Okayama Medical Center in Japan.

Dr. Shimokawahara's discussion with Digital Media Editor Van-Khue Ton covers:

• What the study contributes to the clinical literature with longer-term outcomes of stent-based pulmonary angioplasty in peripheral pulmonary artery stenosis (PPAS)
• How the diffuse nature of PPAS and the advanced stage of disease complicates treatment options
• The evolution of stent choices and technologies in the last 20 years of clinical practice at their center
• Ideal follow-up conditions for monitoring patients after PPAS stenting

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Today, JHLT: The Podcast discusses "Long-term effects of medical therapy pre- and post-pulmonary endarterectomy—insights from the UK CURATE registry," a manuscript available online now and in the September print issue of JHLT.

Today's guest is first author Paula Appenzeller, MD, of the National Pulmonary Vascular Diseases Unit at Royal Papworth Hospital in Cambridge.

In the episode, Dr. Appenzeller and the editors discuss:

• How findings from the UK CURATE registry challenge assumptions about pre-operative therapy in CTEPH
• What's important about the 6-minute walk distance test
• How hemodynamics help guide post-PEA treatment decisions
• If multimodal CTEPH treatment could become the norm

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, JHLT: The Podcast explores the study "The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction," which appears in the August print issue of JHLT.

Today's guest is Daniel C. Chambers, MBBS, MD, of The Prince Charles Hospital and Queensland Lung Transplant Service in Brisbane, Australia.

From across the dateline, he and Digital Media Editor Erika Lease discuss:

• What inspired the team to explore the use of mesenchymal stromal cell (MSC) infusions in CLAD patients
• Preparation and treatment considerations for using MSCs
• How despite the negative outcome—the MSCs made no clear improvements in the patient groups—the study still pushes the field forward

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Today, JHLT: The Podcast discusses "Improved outcomes and donor utilization in heart transplantation with 10 °C static cold storage," a manuscript available online now and in the August print issue of JHLT.

Today's guest is senior author John Trahanas, MD, of the Vanderbilt University School of Medicine in Nashville, TN USA.

In the episode, Dr. Trahanas and the editors discuss:

• What was learned from the lung 10°C trials and how the team adapted the devices for hearts
• The improved outcomes in PGD and survivability observed in the 10°C group
• How to determine if switching from ice to 10°C actually changed donor selection practices—and how it enabled the team to use more hearts

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In case you missed it, JHLT: The Podcast is re-releasing a past audience favorite for your listening pleasure. This month, we revisit a conversation regarding a study from the April 2025 issue of JHLT about the efficacy and safety of sotatercept in patients with PAH.

This conversation with Ioana Preston, MD, of the Tufts University School of Medicine in Boston, explores:

• What makes sotatercept unique as the first "biologic" in the treatment of PAH
• Hypotheses about the mechanism of action in sotatercept
• Sotatercept's interaction with mPAP and what it indicates about the drug's action on the pulmonary vasculature

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

JHLT: The Podcast returns for July with a paper entitled "Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: Results from the Trifecta-Heart study," available online now and in the July print issue of JHLT.

Today's guests are first author Katelynn S. Madill-Thomsen, PhD and senior author Philip F. Halloran, MD, PhD, both from the Alberta Transplant Applied Genomics Center in Canada.

In the episode, the authors and editors discuss:

• Striking similarities—and key differences—in the DSA-negative and DSA-positive groups
• Changes to clinical practice based on the findings, including innovations from the kidney transplant community
• Future studies, including tools and therapies that could be explored for improved clinical outcomes

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

For the first time, JHLT: The Podcast welcomes a patient onto the podcast. The Digital Media Editors are pleased to welcome heart transplant recipient and patient advocate Payton Herres for a discussion about her recent perspective piece in JHLT.

In this compelling, moving discussion, Payton shares:

• Her treatment story—from her congenital diagnoses to her life-changing transplant—and her donor's story
• The difference between coverage and access—and how FDA labeling affected her access to an important component of her care
• What she wishes clinicians understood about long-term care of transplant patients

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

On JHLT: The Podcast, we kick off June with a paper entitled "Serial assessment of modified Society for Cardiovascular Angiography and Interventions SHOCK classification in post-cardiotomy patients," which is available online now and in the June issue of JHLT.

Today's guests are first author Ufuk Baldan, MD and senior author Patrick Klein, MD, PhD, both of the Amsterdam University Medical Center in the Netherlands.

We discuss:

• The heterogeneous nature of post-cardiotomy shock and challenges to treat
• Should serial assessments become standardized post-cardiac surgery?
• Does SCAI staging overestimate risk—and how do we interpret the stages we observe immediately post-op?
• What's next for this line of research?

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

On this special episode of JHLT: The Podcast, the Digital Media Editors take a look back at the exciting science that was on display at ISHLT2026, the ISHLT 46th Annual Meeting & Scientific Sessions.

Topics include:

• Artificial intelligence and machine learning in transplantation, especially in assessing donor lungs and EVLP
• Cardiogenic Shock science at ISHLT2026, including a well-attended, all-new Academy
• The re-launch of the ISHLT International Thoracic Organ Transplant Registry, and the recent report in JHLT

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.